xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
Treasury Wine Estates Shares Surge After U.S. Dispute Settlement and Earnings Upgrade 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
Amazon Explores AI Content Marketplace With Media Publishers 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
MALVERN, Pa., April 05, 2018 -- PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing therapies for the treatment of orphan diseases, today announced that it has completed dosing in the first cohort of subjects in its Phase 1 clinical trial of PB2452 (formerly MEDI2452), a reversal agent for the antiplatelet therapy ticagrelor.
The randomized, double-blind, placebo-controlled, single ascending dose trial is evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous PB2452 with and without ticagrelor pre-treatment in up to nine cohorts and a total of approximately 60 healthy volunteers.
“PB2452 has the potential to rapidly and specifically reverse the antiplatelet effects of ticagrelor in rare emergency situations, like urgent surgery or severe bleeding, providing a unique differentiator among oral P2Y12 antagonist antiplatelet agents,” said John Lee, M.D., Ph.D., Chief Medical Officer of PhaseBio. “In preclinical studies, PB2452 demonstrated high affinity and specific binding to ticagrelor, and was shown to reverse ticagrelor-mediated inhibition of platelet aggregation and to normalize bleeding.i PhaseBio in-licensed PB2452 from MedImmune in November 2017, and we are thrilled with its rapid progression into clinical trials.”
About PB2452
PB2452 (formerly MEDI2452) is a neutralizing Fab antibody fragment that binds to ticagrelor and its active metabolite AR-C124910XX, and is intended to reverse the antiplatelet effects of ticagrelor. The availability of PB2452 would enable reversal of the antiplatelet effects of ticagrelor in rare emergency situations and greatly reduce the waiting period before surgery.
About PhaseBio
PhaseBio Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company developing therapies for the treatment of orphan diseases. PhaseBio is leveraging its proprietary elastin-like polypeptide (ELP) biopolymer technology platform to develop therapies with the potential for less-frequent dosing and better patient compliance. PhaseBio’s lead development candidate, PB1046, is a first-in-class weekly vasoactive intestinal peptide (VIP) receptor agonist for the treatment of pulmonary arterial hypertension. The company is also developing PB2452, a reversal agent for the antiplatelet therapy ticagrelor. PhaseBio is privately owned, with headquarters and research laboratories in Malvern, PA. For more information, please visit www.phasebio.com.
Media Contact:
Laura Bagby, 6 Degrees
(312) 448-8098
[email protected]
i Buchanan A, Newton P, Pehrsson S, et al. Structural and functional characterization of a specific antidote for ticagrelor. Blood. 2015; 125(22): 3484-3490. doi:10.1182/blood-2015-01-622928.
